Method for the treatment of gastroduodenal ulcers

 

(57) Abstract:

The invention relates to medicine, namely to a gastroenterologist, and can be used for the treatment of gastroduodenal ulcers. When fibrogastroduodenoscopy cut away along the perimeter of the ulcer defect in 4 points. For this purpose, 2 ml (100 mcg) of Sandostatin in breeding with 8 ml of 0.25% solution of novocaine. The chip is carried out 1 every 2 days for 14 days. The method can reduce the secretory activity and enhance regeneration of the gastric mucosa. This reduces the possible scarring ulcers. 1 C.p. f-crystals, 2 tab.

The invention relates to medicine, namely to a gastroenterologist, and can be used for the treatment of gastroduodenal ulcers.

The problem of ulcers takes a Central place in modern gastroenterology. This is due to its prevalence, and social significance. If since the mid 70-ies of the monograph dedicated to peptic ulcer, published with a frequency of one monograph in 10 years, in the next 20 years - with a frequency of one monograph in 2-3 years. This is due, primarily, with technological progress, which greatly accelerates the period of accumulation of knowledge and new data, the call is on, L. C. Maslovsky "peptic Ulcer disease", M, 1995).

Peptic ulcer and duodenal ulcer is observed in the 0.4 - 10% of the population. According to A. L. Grebneva (Modern advances in the diagnosis and treatment of diseases of the digestive system. In kN. New in gastroenterology. M, 1995), on the territory of the former USSR in 1989, only registered patients with peptic ulcer of stomach and duodenum was about 10 million, the Increasing incidence, which reaches 5.7 per 1000 population, chronic relapsing course, long-term scarring, frequent complications requiring complex surgical procedures, long term disability and disability of patients, can be attributed to the pathology of a number of important medical and social problems. So for the period from 1971 to 1985 frequency SUD increased 1.8 times, the mortality rate was 11.4%, with forecasts for the period 1986 to 2010 is expected to further increase in the incidence of still 1.8 times.

The present work is devoted to the practical issues of peptic ulcer. Basically, today, conservative treatment of peptic ulcer disease associated with drug therapy. Current views on the etiology and pathogenesis of p. pain and dyspeptic phenomena; the healing of ulcers; reducing signs of acute gastritis and duodenitis (meaning, primarily, forms, called pyloric Helicobacter populating); normalization of gastroduodenal motility; preventing the aggravation or extension of the period of remission.

Gastroduodenoscopy, having direct access to the plague, has opened up new possibilities in the treatment of this disease. This method allows the introduction or application of a drug for ulcerative defect, while the parenteral method of administration access to the limited ulcer inflammatory shaft, granulation tissue, impaired microcirculation in periultseroznoy area.

There are several ways local impact on the ulcer by endoscopy (O. N. Minushkin, I. C. Animals, A. Elizaveta, L. C. Maslovsky "peptic Ulcer disease", M, 1995):

1. Machining ulcer crater with biopsy forceps, brushes or wash in a strong jet of fluid through the catheter.

2. Treatment of the ulcer liquid substance through the catheter. Offer to clean the ulcer alcohol, collargol, 5-10% solution of silver nitrate, rosehip, sea buckthorn oil, solkoseril (BHT, solcoseryl gel on the base).

4. The application of film-forming substances. Apply aerosol medications (liphuzol, gastrosil, statical) and medical adhesives (BF-6, MK-6, MK-7, MK-8, CL-3, propolicy glue).

5. Treatment of ulcer crater and periultseroznoy zone with application of high frequency currents.

6. Phototherapy with low - and high-energy laser radiation.

7. Transendoscopic ultrasound therapy.

8. Around the ulcer, periultseroznoy zone, the gastroduodenal area of drug drugs. This method is the introduction of drugs with anti-inflammatory action (hydrocortisone, heparin), improving the regeneration (methyluracil, solcoseryl, oxyphenisatin, dalargin, etc). According to most authors, using methods of local impacts on the ulcer through the endoscope, such treatment can significantly reduce the possible scarring ulcers of the stomach and duodenum.

The nearest proposed method of local treatment of ulcers is around the ulcer Dalargin (O. A. Kargin, Local use of Dalargin and electrostimulation during endoscopic who, however, it is possible the formation of a rough scar, the drug has no effect on the level of secretion of hydrochloric acid, to accelerate healing time.

The objective of the invention is to increase the effectiveness of treatment of gastroduodenal ulcers-drug, which provides a complex effect on the ulcer by reducing the secretory activity of the mucous membrane, by increasing the regenerative activity due to possible impacts on the HP factor.

Our data suggest that this drug is Sandostatin, which is imposed on this invention in the region of the ulcer.

The method is as follows. The patient is fibrogastroduodenoscopy lying on left side. After examination of the stomach and duodenum, assess the condition and size of the ulcer, with the help of the endoscopic injector drawn through the instrument channel of the endoscope, is around the ulcer, 4 points around the perimeter at a distance of 1 cm from the edges of the ulcer, with the introduction of a solution of Sandostatin in the submucosal layer. Manipulations are performed once every two days. All 7 sessions. For injections ispolzuetsia, i.e. 2 ml of Sandostatin diluted in 8 ml of novocaine.

Clinical example 1

Patient C., 36 years old, was admitted to the hospital with complaints of pain in the epigastric region without a clear connection with food intake, nausea. For 11 years, suffering from gastric ulcer with annual exacerbations. Described in the complaint occurred two days ago. When admitted to hospital, General condition closer to satisfactory HELL 120/75 mm RT. century, the heart rate is 80 beats per minute, blood haemoglobin 125 g/l At esophagogastroduodenoscopy revealed a mucosal defect in the anterior wall of the antrum of the stomach, up to 0.8 cm in diameter, surrounded by inflammatory shaft with perifocal hyperemia of the mucous performed fibrin. Started by local treatment by the proposed method. After the first session on the second day reached the relief of pain, symptoms of dyspepsia. On the third day, repeat the procedure and the lack of perifocal hyperemia of the mucous. During the next session of the local treatment of endoscopically ascertained reducing the size of the ulcer to 0.4 cm in diameter, the beginning of epithelialization, the surface location of the ulcer. On the ninth suck Inoi C., 27 years. History of peptic ulcer disease duodenal ulcer within 3 years. Complaints received at a aching epigastric pain, left upper quadrant with radiation to the lumbar region, nausea, lack of appetite, loose stools. The General state of moderate severity: body temperature to 37.8oC, flushing of the face, abdomen moderately swollen, with marked tenderness to palpation in the epigastrium. Blood leukocytosis, 10.2 thousand Moderate increase in the level of diastase in the urine. In conclusion, ultrasound - reactive pancreatitis. During esophagogastroduodenoscopy in front of the bulb of the duodenum revealed rounded ulcerative defect: deep, up to 1.0 cm, the bottom of which is covered with fibrin and necrotic masses. For local treatment to 6 days recorded cleansing, reducing the depth of the ulcer, and 9 day - pronounced edge epithelialization, reduced to 0.3 see Clinically is the absence of pain, subsidence of the clinic pancreatitis, ultrasound improved the condition of the pancreas. On the 12th day endoscopically showed complete epithelialization of ulcers.

To evaluate the effectiveness of the developed method, we have conducted with the treatment of the developed method (n1= 12). In the first control group included patients who were treated using a method prototype endoscopic injections ulcer solution of Dalargin (n2= 12). The second control group consisted of patients who were around the ulcer 0.25% solution of novocaine, without Sandostatin, according to the method and in the amount stipulated in the treatment developed by the proposed method (P3= 10).

In all groups, patients were assigned to diet, recommendations for diet. Patients in all groups comparable in age, sex, ulcer history, the size of the ulcers. The average age of patients in group 1, 42 years old, in the first control - 41.5 years, in the second control group for 42 years. The ratio of men and women in all groups of 3:1. The average duration of ulcer history in the main group was 7.5 years, in the first control - 6.9 years, in the second control group is 7.6 years. Patients in all groups of complications in history was not. The size of the ulcer at admission in all groups - from 0.7 cm to 1.3 cm (PL. 1).

We have analyzed the results of treatment in the main and control groups. It has also been found earlier by mensentaal - for 12 hours, respectively. Terms of ulcer healing by 100% in the main group - 9 days, 1 control for 12 hours, and in 2 control group time exceed 15 days. In addition, identified earlier reduction of perifocal inflammation, lymphoplasmacytic infiltration in the main group compared to the control. In the main group recorded the beginning of epithelialization in 6 days, while 1 and 2 control groups, 9 and 12 days respectively. The relief of pain, dyspepsia events in the main group in the period up to 3 days, in the control - 6-9 days. Cytologic evaluation noted sanitizing effect in the main group compared to HP. The results of comparative studies are reflected in the table. 2).

Thus, local application of sandostatin in the treatment of gastroduodenal ulcers by the developed technique has a pronounced reparative and clinical effect.

1. Method for the treatment of gastroduodenal ulcers, including around the submucosal layer around the perimeter of the ulcer with a solution of a drug in therapeutic fibrogastroduodenoscopy, characterized in that as a medicinal PRA of novocaine.

2. The method according to p. 1, characterized in that the chip is at 4 points around the perimeter of the ulcer, with a frequency of 1 every 2 days for 14 days.

 

Same patents:

The invention relates to medicine, namely to balneotherapy, and can be used in rehabilitation of patients with gastroduodenal pathology with hypersecretory syndrome in the medical-preventive establishments of sanatorium type, clinical

The invention relates to the production of chemical and pharmaceutical products and is designed to produce 5-aminosalicylic acid, are acceptable for pharmaceutical purposes
The invention relates to medicine, namely to a gastroenterologist, and for the treatment of chronic gastritis, gastric ulcer and duodenal ulcer
The invention relates to medicine, gastroenterology, and for the treatment of patients with pyloroplasty ulcers, combined with duodenogastric reflux

The invention relates to medicine, in particular to a gastroenterologist may be used for the treatment of patients with peptic ulcer of stomach and duodenum, which is manifested by pains in the epigastric region, nausea, vomiting, diarrhoea phenomena

The invention relates to a derivative pyrrolopyridine or their pharmaceutically acceptable salts, with high activity, inhibiting the secretion of gastric juice; activity, protects the mucous membrane of the stomach; and high antibacterial activity against Helicobacter pylori; and antiulcer agent containing the derivative or salt as an active ingredient
The invention relates to medicine, namely to Oncology, and can be used for the treatment of malignant tumors of the pancreas

The invention relates to therapeutic peptides

FIELD: organic chemistry, amino acids.

SUBSTANCE: invention claims new compounds that elicit both high affinity and selectivity with respect to neuromedin B and somatostatin receptors. Compounds has the following formula: wherein α-atom in each group among AA1, AA2, AA3, AA4, AA5, AA6, AA7 and AA8 is substituted optionally and independently with (C1-4)-alkyl-(C3-4)-alkenyl, (C3-4)-alkynyl or (C1-6))-alkyl-C(O)-; AA1 is absent or means Ac-D-Phe or D- or L-isomer of R11, Pip, Pro or aromatic α-amino acid taken among the group consisting of Cpa, Dip, Nal and Phe; AA2 is absent or means Pal, Phe, Tyr; AA3 means D- or L-isomer of Cys; AA4 means D- or L-isomer of Trp; AA5 means Lys; AA6 means D- or L-isomer of Cys; AA7 is absent or means A3c, A4c, A5c, A6c, Abu, Aic, β-Ala, Gaba, Nle, Pro, Sar, Thr, Thr(Bzl) or Val; AA8 is absent or means R11, Nal, Thr, Tyr, Phe or Nle; each among R1 and R2 represents independently hydrogen atom (H) or absent; R5 means -NH2,; R11 means D- or L-amino acid independently in each case and AA3 and AA6 are bound by disulfide bond.

EFFECT: valuable biological properties of compounds.

9 cl, 2 tbl, 1 ex

FIELD: medicine.

SUBSTANCE: the present innovation deals with applying agonists of somatostatin receptors in case of thyroid carcinoma and, it also, deals with the method for modulating the rate of cell proliferation of medullary thyroid carcinoma (MTC) due to combined impact upon cells with either one or several agonists of somatostatin receptors of type 2 (SSTR2)or either with one or several agonists of somatostatin receptors of type 5 (SSTR5). Moreover, the mentioned SSTR5 agonist can be represented with D-Phe-Phe-Trp-D-Trp-Lys-Thr-Phe-Thr-NH2 or its pharmaceutically acceptable salt. The present innovation enables to enhance suppression of MTC cell proliferation due to antagonism between mediated SSTR2 and SSTR5 effects to the proliferation mentioned.

EFFECT: higher efficiency of modulation.

1 cl, 8 dwg, 2 tbl

FIELD: medicine, hormones, chemistry of peptides.

SUBSTANCE: invention describes compound of the formula: cyclo-[{4-NH2-C2H4-NH-CO-O-)-Pro}-Phg-D-Trp-Lys-Tyr-(4-Bzl)-Phe] being not obligatory in protected form, or its pharmaceutically acceptable salt of complex. Compound possesses the inhibitory activity on release of the growth hormone and insulin.

EFFECT: valuable medicinal properties of peptide.

9 cl, 2 ex

FIELD: medicine, pharmacy.

SUBSTANCE: invention relates to a method for treatment of vascular proliferation in a patient. Method involves administration of agonist of somatostatin receptor type 1 in the therapeutically effective dose to a patient wherein indicated agonist of somatostatin receptor type 1 show the inhibition constant value (Ki) lower 5 nM for somatostatin receptor type 1 and its Ki value for somatostatin receptor type 1 at least by 10 times lower as compared with Ki values for each somatostatin receptors type 2, type 3, type 4 and type 5. Invention provides the maximal inhibition of unfavorable vascular proliferation at minimal symptoms of adverse effects based on the selective anti-angiogenic effect of agonist of somatostatin receptor type 1.

EFFECT: valuable medicinal properties of compositions.

12 cl, 3 tbl, 16 dwg

FIELD: medicine.

SUBSTANCE: the present innovation refers to the method for decreasing the rate of cell proliferation of thyroid medullary carcinoma (TMC), the methods of its therapy and visualization which deal with interaction of TMC cells with one or several selective agonists SSTR2 chosen out of the group of compounds consisting of: D-Nal-cyclo[Cys-Tyr-D-Trp-Lys-Val-Cys]-Thr-NH2; cyclo[Tic-Tyr-D-Trp-Lys-Abu-Phe]; 4-(2-hydroxyethyl)-1-piperazinylacetyl-D-Phe-cyclo(Cys-Tyr-D-Trp-Lys-Abu-Cys)-Thr-NH2 and 4-(2-hydroxyethyl)-1-piperazine-2-ethanesulfonyl-D-Phe-cyclo(Cys-Tyr-D-Trp-Lys-Abu-Cys)-Thr-NH2; or their pharmaceutically acceptable salts. The present innovation enables to decrease the rate of TMC cell proliferation and improve the results of its visualization due to selective agonistic action upon SSTR2 along the absence of undesirable effects upon systemic hemodynamics and the values of body metabolism.

EFFECT: higher efficiency.

10 cl, 8 dwg, 2 tbl

FIELD: medicine.

SUBSTANCE: invention refers to medicine, specifically to surgery, and concerns acute pancreatitis prevention associated with direct duodenum surgery. For this purpose 0.01% octreotide solution dosed 5 mkg of dry substance per hour is introduced using intraduodenal probe installed within operation procedure. Introduction is carried out continuously within 3 days after operation. Method provides modelling of physiological regulating mechanism of pancreatic exosecretion duodenal stimulators by inhibited hyperproduction of duodenal peptide stimulators of pancreatic secretion and inflammatory hypostasis of duodenum wall and, as consequence, prevents development of pancreatic intraductal hypertensia, enables to considerably lower rate of acute postoperative pancreatitis at minimisation of octreotide system by-effects.

EFFECT: development of effective method of treatment and prevention of acute pancreatitis associated with direct duodenum surgery.

2 ex

FIELD: medicine.

SUBSTANCE: method provides interaction of cells of a medullary carcinoma of a thyroid gland with agonist SSTR2 representing bond of the formula of cyclo [Tic-Tyr-D-Trp-Lys-Abu-Phe].

EFFECT: reduction of rate of proliferation of cells of thyroid gland medullary carcinoma.

3 cl, 8 dwg, 2 tbl, 1 ex

FIELD: medicine; pharmacology.

SUBSTANCE: parenteral pharmaceutical compositions include somatostatin analogue and tartaric acid.

EFFECT: high stability and simultaneously good local applicability.

8 cl, 10 ex

Treatment method // 2397778

FIELD: medicine.

SUBSTANCE: invention relates to medicine, and deals with treatment of pathologic states connected with increased level of growth hormone (GH) or insulin-like growth factor 1(IGF). For this purpose realised is complex treatment which includes introduction of growth hormone antagonist and somatostatin or somatostatin analogue in developed doses and regimens.

EFFECT: method ensures normalisation of GH and IGF-1 levels in patients resistant to monotherapy with somatostatin analogues during at least 6-month treatment course.

15 cl, 1 tbl, 1 dwg, 1 ex

FIELD: medicine.

SUBSTANCE: invention relates to medicine, namely to surgery, and can be applied for patients with surgical sepsis. For this purpose subcutaneously introduced is sandostatin in dose 100 mkg 5 times per day and roncoleukin in dose 500 thousand IU 1 time per day. Introduction is realised for 2 days and 3 days after operation, as well as in 1 and 2 weeks of post operational period. Simultaneously on the same days during 1 hour hyperbaric oxygenation is carried out with partial pressure of oxygen 1.5-2 atmospheres.

EFFECT: method allows to reduce frequency of fatal outcomes in patients with said pathology due to immunomodelling action, which appears as a result of definite combination of pharmacological medications and hyperbaric oxygenation.

1 ex

FIELD: medicine.

SUBSTANCE: method involves introducing endoscope, clearing injured surface and applying gel produced on Tisol substance base (aqua-complex of titanium glycerosolvate) as medicinal composition via the endoscope. Tisol is administered as aqueous solution of concentration not less than 60% after Tisol. The composition is applied to injured surface in the amount of 2 to 8 ml for one session. The number of treatment sessions is equal to 1 to 7 with 3-5 days long pauses. The composition is prepared by mechanically mixing medicinal microadditives with Tisol substance. The medicinal microadditives are introduced in total amount of 7.26% of composition mass. The ingredients are selected depending on disease. The medicinal composition is applied as 1-2 mm thick layer. When treating the cases of erosion or gastritis, sea-buckthorn oil and/or propolis solution are of preference to be introduced into Thysol as the medicinal microadditives. When treating the cases of gastric or duodenal peptic ulcer, methyluracyl, hydrocortisone, cycloferon or aecol are preferentially introduced into Tisol as the medicinal microadditives. The composition formula is adjusted from session to session on the basis of treatment results visual control and analysis data. Taking meals and drinks is restricted for a patient for half an hour or longer.

EFFECT: enhanced effectiveness in administering drugs into mucous membrane and soft tissues without using needle injectors.

5 cl,4 tbl

Up!